MGMT and central nervous system cancer: Notably, SIRT5 was downregulated in recurrent and secondary gliomas, as well as gliomas with specific genetic characteristics, such as the IDH wildtype, unmethylated MGMT, and 1p19q non-codeletion (Figure 1B).